New Biosimilar approval (biologic generic) may save billions in costs for rheumatoid arthritis patients

man with son The biosimilar adventure continues-Somewhat like generic medicines, A new biosimilar for infliximab or (Remicade) got the approval not from the FDA. What this means is that the medicine works to combat rheumatoid arthritis and Chrohn's disease, but costs much much less that the well-known brand.

lifesaver Interestingly, the medicine was developed by Celltrion and will be co-marketed by Pfizer. The name you will see is Inflectra and it IS a kind of infliximab, but will carry the suffix "-dyyb" to differentiate itself. This is only the second biosimilar to be approved by the FDA. More to follow as always, but we appear to have a new FDA approval that will give similar results while saving literally billions of dollars.

This website is not intended as medical advice, and you should consult your doctor before changing or adding any medicines or vitamins to those you may now be taking and about applying any strategies BEFORE you adopt any approach in this report. While diligent care has been taken to ensure the accuracy of the information provided during the preparation of this edition, no claim is made that all known actions, uses or side effects, strategies for cost containment, targets or cholesterol pathways are included in this report. The accuracy and currentness of information are ever subject to change relative to new guidelines, new information derived from drug research, development and general usage.